Previous 10 | Next 10 |
home / stock / meobf / meobf news
The following slide deck was published by Mesoblast Limited in conjunction with their 2022 Q4 earnings call. For further details see: Mesoblast Limited 2022 Q4 - Results - Earnings Call Presentation
Mesoblast press release (OTCPK:MEOBF): Q2 GAAP EPS of -$4.00. Revenue of $2.38M (+6.3% Y/Y). For further details see: Mesoblast GAAP EPS of -$4.00, revenue of $2.38M
Longeveron has filed proposed terms for a $25 million IPO. The firm is developing a treatment for Alzheimer's Disease and other age-related conditions. LGVN is thinly capitalized and has scant chance of an AD treatment where major pharmas have failed, so I'll pass on the IPO. ...
Strong SACCOVID clinical trial results suggest an approval is forthcoming. Graft versus Host Disease linkage to the most promising therapeutics. Merck business model resonating with investors. Small pool of therapeutic drug companies represents ideal acquisition targets. ...
bluebird bio announces European acceptance of eli-cel gene therapy. Arena Pharmaceuticals completes enrollment for CAPTIVATE trial. Mesoblast suffers a setback as FDA rejects cell therapy application. For further details see: bluebird's European MAA, And Other News: The ...
Japanese High In 1989, the Japanese Nikkei hit 38,916. It was a time of craziness. The Emperor's palace was valued at equal to all of the real estate in California. Such prices are unsustainable. The Nikkei 30 years out sits at 23,205. Someday, the high point of the Nikkei will be surpassed,...
Calithera signals terminating partnership with Incyte Calithera Biosciences Inc. ( CALA ) reported that it has sent a written intimation to Incyte ( INCY ) terminating their collaboration and licensing agreement. The termination will be effective from September 30. The companies had entere...
Mesoblast Limited (MESO) Q4 2020 Earnings Conference Call August 26, 2020 6:00 P.M. ET Company Participants Silviu Itescu - Chief Executive Officer and Managing Director Josh Muntner - Chief Financial Officer Fred Grossman - Chief Medical Officer Conference Call Participants ...
The following slide deck was published by Mesoblast Limited in conjunction with their 2020 Q4 earnings Read more ...
TG Therapeutics reports development for Umbralisib TG Therapeutics Inc. ( TGTX ) reported that the FDA has accepted its New Drug Application for umbralisib. The drug candidate will be reviewed under the Priority Review pathway. It had been granted Breakthrough Therapy tag for treating ma...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr. Itescu reiterated that the Company expects to file this quarter the Biologics License Applicati...
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2024. Mesoblast Chief Executive Silviu Itescu said: ȁ...